Reaction
Non-Small Cell Lung Cancer Recurrent reporting signals
As of the last recalculation, Non-Small Cell Lung Cancer Recurrent appears in 274 FAERS reports alongside 9 co-occurring drug terms. The strongest observed disproportionality signal is DURVALUMAB (PRR 298.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Durvalumab | 62 | 298.9 | 299.8 |
| Gefitinib | 18 | 162.1 | 162.4 |
| Osimertinib | 43 | 120.7 | 120.9 |
| Pemetrexed | 18 | 68.2 | 68.2 |
| Pemetrexed Disodium | 26 | 57.2 | 57.2 |
| Dabrafenib | 15 | 57.2 | 57.2 |
| Trametinib | 13 | 42.9 | 42.9 |
| Erlotinib | 5 | 39.9 | 39.9 |
| Erlotinib Hydrochloride | 5 | 30.9 | 30.9 |